Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Drug Mycobutin Granted First Mycobacterosis Approval In Japan

This article was originally published in PharmAsia News

Executive Summary

Pfizer announced July 16 that it obtained approval to manufacture and market its mycobacterosis drug Mycobutin (rifabutin). It's the first mycobacterosis drug in Japan. Rifabutin is also indicated to treat non-tuberculosis mycobacteri and multidrug-resistant tuberculosis. The drug is to treat the onset of MAC that is common among HIV carriers. Approved in 35 countries, Pfizer applied for approval with the Ministry of Health, Labor and Welfare last June. In Japan, the tuberculosis rate is 2.6 per 100,000 people, with around 26,000 people diagnosed each year. That's 1.5 time higher than in the UK and 5 times of the U.S. (Click here for more - Japanese language

You may also be interested in...

CV Sciences Reboots PlusCBD Brand While Counting On New Immunity Products During Flu Season

CV Defense, the second launch in the firm’s new immune-support line (without cannabidiol), is built around palmitoylethanolamide and other nutrients and botanicals to “optimize immune response.” CV Sciences touts the immunity range as complementary to its PlusCBD brand, which is in the process of rolling out dozens of new products in updated packaging.

Finance Watch: Have Investors Reached IPO Fatigue?

Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.

Expediting The Expedited: How Rolling CMC Review Process Is Working For COVID-19 Vaccines

US, EU and Canadian authorities recently discussed their approaches to rolling reviews of CMC applications for coronavirus vaccines.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts